What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Once daily tablet dosing for 48 weeks, starting at Week 16 visit”In the company’s words, NCT07762027 on ClinicalTrials.gov
- Tested for
- Chronic Hepatitis D Infection, Mild Hepatic Imparement
- Main trialPhase 2
- “This study is designed to assess safety, pharmacokinetics, and efficacy ABI-6250 in participants with Chronic Hepatitis D Virus Infection.”In the company’s words, NCT07762027 on ClinicalTrials.gov
Other drugs for Chronic Hepatitis D Infection
- ElebsiranVir Biotechnology, Inc. · Phase 3
- TobevibartVir Biotechnology, Inc. · Phase 3
- BrelovitugMirum Pharmaceuticals, Inc. · Phase 3
- HepalatideShanghai HEP Pharmaceutical Co., Ltd. · Phase 3
- LibevitugHuahui Health · Phase 3
- GS-4321Gilead (Kite) · Phase 1/2
Coming up2
- Apr 2027Phase 1 trial completes · ClinicalTrials.gov
- Jun 2027Phase 2 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 19 NovStatus changed: Not yet recruiting to Recruiting · ClinicalTrials.gov NCT07850999
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Not yet recruiting | Jun 2027 | A Study to Assess the Safety, Pharmacokinetics, and Efficacy of ABI-6250 in Participants With Chronic Hepatitis D Virus Infection | |
| Phase 1Recruiting | Apr 2027 | A Study to Assess the Safety, Tolerability and Pharmacokinetics of ABI-6250 in Participants With Mild Hepatic Impairment Compared With Participants With Normal Hepatic Function | |
| Phase 1Completed | 8 Jul 2025 | A Study to Assess the Safety, Tolerability and Pharmacokinetics of ABI-6250 in Healthy Participants |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026